Avalon GloboCare Corp. is a commercial-stage company engaged in developing and delivering precision diagnostic consumer products and the advancement of intellectual property in cellular therapy. The Company operates in two reportable business segments: the real property operating segment and the laboratory testing services segment. Its laboratory services offer a test menu that satisfies the clients' testing needs, from general bloodwork to anatomic pathology, urine toxicology, pharmacogenomics (PGx) testing and more, and it is a one-stop-shop for clinical testing. The Company is currently marketing the KetoAir breathalyzer device and plans to develop additional diagnostic uses of the breathalyzer technology. The KetoAir breathalyzer is a handheld device that allows the user to detect acetone levels in exhaled breath. The acetone level is in concentration units part-per-million (ppm) such that the user knows the real-time ketosis status.
Overvalued
The company’s latest PE is -0.06, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 83.03K shares, decreasing 34.57% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.22.